Trial
NCT04158700
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Eli Lilly and Company
Collaborators
Merck Sharp & Dohme LLC
Condition
Advanced Cancer
Intervention
LY3200882
Why stopped
The withdrawal is due to a strategic realignment and is not related to any particular safety or efficacy concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-02-19